Sparrow

Targeted cardiometabolic therapeutics

Sparrow Pharmaceuticals is a targeted cardiometabolic therapeutics company delivering improved outcomes for patients who struggle to control diabetes and related metabolic conditions with current options.

The company’s lead candidate, clofutriben, is a first-in-class, once-daily, oral HSD-1 inhibitor initially in development for the millions of patients with type 2 diabetes and elevated cortisol. HSD-1 inhibition complements existing antidiabetic agents by addressing a cause of disease progression and treatment resistance across a spectrum of metabolic dysfunction. Clofutriben has been associated with improved glycemic control while generally safe and well tolerated in multiple clinical trials without requiring dose titration.